{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:59Z","timestamp":1786119659836,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1097\/inf.0b013e3182054ab9","type":"journal-article","created":{"date-parts":[[2010,12,31]],"date-time":"2010-12-31T12:27:09Z","timestamp":1293798429000},"page":"e41-e48","source":"Crossref","is-referenced-by-count":55,"title":["Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults 10 to 25 Years of Age"],"prefix":"10.1097","volume":"30","author":[{"given":"Roger","family":"Baxter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaela","family":"Baine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Ensor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard R.","family":"Friedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-30-20210202","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998\u20132007: implications for prevention of meningococcal disease.","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R2-30-20210202","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.yapd.2005.03.005","article-title":"Meningococcal infections at the start of the 21st century.","volume":"52","author":"Brandtzaeg","year":"2005","journal-title":"Adv Pediatr"},{"key":"R3-30-20210202","first-page":"1","article-title":"Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"54","author":"Bilukha","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"R4-30-20210202","first-page":"273","article-title":"Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use\u2013Advisory Committee on Immunization Practices (ACIP).","volume":"59","year":"2010","journal-title":"Morb Mortal Wkly Rep"},{"key":"R5-30-20210202","first-page":"794","article-title":"Revised recommendations of the Advisory Committee on Immunization Practices to Vaccinate all persons aged 11\u201318 years with meningococcal conjugate vaccine.","volume":"56","year":"2007","journal-title":"Morb Mortal Wkly Rep"},{"key":"R6-30-20210202","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-2567.2004.01971.x","article-title":"Haemophilus influenzae type b conjugate vaccines.","volume":"113","author":"Kelly","year":"2004","journal-title":"Immunology"},{"key":"R7-30-20210202","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/14760584.8.3.265","article-title":"Prevention of meningococcal serogroup C disease by NeisVac-C.","volume":"8","author":"Borrow","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"suppl 2","key":"R8-30-20210202","doi-asserted-by":"crossref","first-page":"B20","DOI":"10.1016\/j.vaccine.2009.04.067","article-title":"Meningococcal C conjugate vaccine: the experience in England and Wales.","volume":"27","author":"Campbell","year":"2009","journal-title":"Vaccine"},{"key":"R9-30-20210202","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vaccine.2008.08.075","article-title":"Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15\u201325 years.","volume":"27","author":"\u00d8stergaard","year":"2009","journal-title":"Vaccine"},{"key":"R10-30-20210202","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.vaccine.2009.10.064","article-title":"A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children.","volume":"28","author":"Knuf","year":"2010","journal-title":"Vaccine"},{"key":"R11-30-20210202","first-page":"1","article-title":"Recommended immunization schedules for persons aged 0 through 18 years\u2014United States, 2010.","volume":"58","year":"2010","journal-title":"Morb Mortal Wkly Rep"},{"key":"R12-30-20210202","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays.","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"R13-30-20210202","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus: part I. The role of humoral antibodies.","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"R14-30-20210202","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/JCM.32.6.1475-1482.1994","article-title":"Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay.","volume":"32","author":"Gheesling","year":"1994","journal-title":"J Clin Microbiol"},{"key":"R15-30-20210202","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2165\/00003495-199855030-00003","article-title":"Meningococcal vaccines. Current status and future possibilities.","volume":"55","author":"Peltola","year":"1998","journal-title":"Drugs"},{"key":"R16-30-20210202","first-page":"149","article-title":"Serologic response to serogroup C meningococcal vaccine in Brazilian preschool children.","volume":"16","author":"Amato Neto","year":"1974","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"R17-30-20210202","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1086\/317646","article-title":"Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.","volume":"183","author":"Richmond","year":"2001","journal-title":"J Infect Dis"},{"key":"R18-30-20210202","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/INF.0b013e3181b9a831","article-title":"A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months.","volume":"29","author":"D\u00edez-Domingo","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R19-30-20210202","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.vaccine.2008.01.022","article-title":"Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases.","volume":"26","author":"Bardotti","year":"2008","journal-title":"Vaccine"},{"key":"R20-30-20210202","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"key":"R21-30-20210202","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1086\/599117","article-title":"Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed ACWY conjugate vaccine in adolescents.","volume":"49","author":"Jackson","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R22-30-20210202","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpedi.159.10.907","article-title":"Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.","volume":"159","author":"Keyserling","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R23-30-20210202","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/INF.0b013e31818a0237","article-title":"A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents.","volume":"28","author":"Jackson","year":"2009","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006454-201103000-00030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:51:18Z","timestamp":1786042278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006454-201103000-00030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e3182054ab9","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}